Middle East Veterinary Vaccines Market is expected to reach US$ 533.4 Million by 2031, reflecting a cumulative CAGR of 4.8% over the forecast period (2022-2031)
[192 Pages Report] According to a recent study by Future Market Insights (FMI), the Middle East Veterinary Vaccines Market is expected to witness moderate growth during the forecast period. The market is expected to grow from US$ 335.0 Mn in 2021 to over US$ 533.4 Mn by 2031. This reflects a cumulative CAGR of around 4.8% over the forecast period (2021-2031).
The demand for veterinary vaccines has increased over the past few years due to the increasing incidences of foodborne and zoonotic infections amongst the population in the Middle Eastern region. The pattern of veterinary treatment is shifting from curative/reactive to preventive in these countries. The cost of preventive treatment is much smaller and has far fewer side effects than reactive treatments that often lead to mass slaughter.
To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-MA-3086
The rebound of economic prosperity in MEA markets is expected to contribute towards increased demand for processed healthy meat products. This will fuel the demand for effective vaccination of livestock, especially in major animal farming and meat-producing nations in the region with a diversified herd such as Sudan, Turkey, Egypt and KSA.
Rising per capita disposable income levels are largely contributing towards demand for processed food items. This is expected to drive the growth of veterinary vaccines in poultry and livestock segments.
The key players of the veterinary vaccines industry are focusing on finding innovative products to control zoonotic infection rates. Along with this, various advancements in biotechnology are expected to create a favourable platform for the development of various veterinary vaccines in developing markets such as UAE, KSA, Turkey and Jordan. These techniques include next-generation sequencing, synthetic biology and systems biology, among others.
Further, continued investments in multi-disciplinary vaccinology research could improve vaccine development efficiency and shorten time-to-market for upcoming veterinary vaccines.
Key players are working on innovative products, conducting acquisitions, mergers, agreements with other companies to improve their market presence and tap into less competitive emerging markets.
For instance, In September 2018, Boehringer Ingelheim announced that they would be donating 75,000 doses of rabies vaccines to the Global Alliance for the Rabies Control, as an effort of recognition of World Rabies Day on September 28th.
Such developments not only strengthen the company’s existing portfolio but also help to increase their presence at the regional as well as global level, and help companies to sustain the increasing competitive pressure.
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3086
Key Takeaways from Middle East Veterinary Vaccines Study
- The attenuated live vaccines accounted for 35.1% share of the total market of veterinary vaccines in the Middle East in 2021. The demand for attenuated live vaccines is expected to grow at a CAGR of 5.8% over the forecast period. By triggering a wide spectrum of immune responses, attenuated vaccines can deliver better immunity than conventional vaccinations.
- The livestock animals held the maximum share of 73.9% of the total veterinary vaccines market in terms of animal in 2021. Increased demand for processed meat products and making animal health a critical component of disease control is leading to increasing adoption of livestock animal’s vaccination in the Middle Eastern region.
- The foot and mouth disease accounted for more than 27% of the market share of the Middle East veterinary vaccines market in 2021. Foot and mouth disease is the most commonly occurring disease amongst all the animals. This segment is expected to project a cumulative CAGR of 5.6% over the forecast period.
- The private veterinary pharmacies registered sales worth U.S. $ 114.6 Mn during the year 2021 and are expected to project a cumulative CAGR of 5.0% over the forecast period. Increased awareness regarding animal vaccinations, rising incidences of foot and mouth disease and high demand for good quality processed meat are some of the factors contributing to the growth of private veterinary pharmacies in the Middle East.
“Increased demand for processed meat products around the world will drive the demand for veterinary vaccines market in the Middle East,” says the FMI Analyst.
Who is winning?
The key manufacturers of the veterinary vaccines market are adopting strategies such as partnership strategies for global expansion and improving their hold over the global market.
- In January 2021, Merck Animal Health announced the acquisition of Poultry Sense Ltd, which provides health and environmental monitoring solutions for the poultry industry.
- In September 2019, Ceva, in partnership with Biotecon diagnostics, announced the launch of their latest product, a real-time diagnostic kit that will help the poultry producers to fight salmonella infections in their farms.
The key market players of the Middle East veterinary vaccines market include JOVA, Bioveta, Inc., Intervac Pvt. Ltd., Zoetis, Elanco, Merial, Merck & Co. Inc, Bayer Pharma AG, Ceva and Boehringer Ingelheim.
Want more insights?
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The Middle East veterinary vaccines market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The study provides compelling insights into the Middle East veterinary vaccines market. The veterinary vaccines market is segmented into five parts based on vaccine type (attenuated live vaccines, inactivated vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines, and others) based on animal type (companion animals, livestock animals and equine) based on disease indication (foot and mouth disease, NewCastle disease, PPRS, canine parvovirus, brucellosis, avian influenza, and others), based on end-user (hospital pharmacies, veterinary clinics, private veterinary pharmacies and others) and based on country ( KSA, UAE, Turkey, Jordan, Sudan, Egypt and Rest of MEA).
For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-3086
Middle East Veterinary Vaccines, by Category
- Attenuated Live Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- DNA Vaccines
- Recombinant Vaccines
- Companion Animals
- Livestock Animals
- Small Ruminant
By Disease Indication:
- Foot and Mouth Disease
- Newcastle Disease
- Canine Parvovirus
- Avian Influenza